Private equity firm Brighton Park Capital has fully exited its investment in Bengaluru-based digital healthcare solutions company Indegene, selling its entire 8.73% stake for approximately ₹1,105 crore through block deals executed on August 6. The exit marks the conclusion of the firm’s investment in the healthcare technology company, which debuted on the stock exchanges in 2024.
According to Indegene’s June 2026 shareholding pattern, the Greenwich-based private equity investor held its stake through two special purpose vehicles (SPVs). The shares were offloaded in multiple block transactions on the stock exchanges, though the identities of the buyers were not immediately disclosed.
Brighton Park Capital had first invested in Indegene in 2021, alongside Carlyle, as part of a $200 million investment aimed at supporting the company’s global expansion and strengthening its position in the healthcare technology and life sciences services sector.
The latest transaction follows a series of stake sales by early investors after Indegene’s public listing. Earlier, Carlyle had also completed its exit from the company through multiple market transactions, reflecting the typical monetisation strategy adopted by private equity investors after a successful IPO.
About Indegene
Indegene is a Bengaluru-headquartered healthcare technology company that provides digital transformation, commercialization, and medical affairs solutions to global pharmaceutical, biotechnology, and medical device companies. The company combines domain expertise with technology platforms to help life sciences firms improve clinical development, regulatory compliance, and commercial operations.
Key Highlights
- Seller: Brighton Park Capital
- Company: Indegene
- Stake Sold: 8.73%
- Deal Value: Approximately ₹1,105 crore
- Transaction Type: Block deals
- Date: August 6, 2026
- Investment Vintage: 2021
- Sector: Healthcare technology and life sciences solutions
